ADMA
ADMA Biologics, Inc.
ADMA's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over ADMA overall, supported by stronger modeled upside and lower modeled downside.
ADMA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Strong |
ADMA's profitability, cash flow and balance sheet are currently strong, and its revenue is stable.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ADMA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 14x | $10.76 | -19% |
| Forward | 16x | $13.24 | — |
| Current | 17x | $13.24 | — |
| Fair | 21x | $16.22 | +23% |
| Expensive | 66x | $50.55 | +282% |
Historical ranges are pointers, not guarantees.
ADMA has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ADMA Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for ADMA, with profitability improving.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ADMA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.81 | +5.6% |
| Q3 2026 | $0.77 | -9.4% |
| Q2 2026 | $0.70 | -18% |
| Q1 2026 | $0.68 | -19% |
| Q4 2025 | $0.60 | -26% |
| Q3 2025 | $0.85 | +204% |
| Q2 2025 | $0.85 | +507% |
| Q1 2025 | $0.84 | +$0.86 |
| Q4 2024 | $0.81 | +$0.94 |
ADMA earned $0.77 per share over the past year, down 9.4% from the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ADMA on earnings, with more consistent year-over-year improvement.
ADMA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $141.1M | +5.1% |
| Q2 2026 | $124.4M | +2% |
| Q1 2026 | $114.5M | -0.3% |
| Q4 2025 | $139.2M | +18% |
| Q3 2025 | $134.2M | +12% |
| Q2 2025 | $122M | +14% |
| Q1 2025 | $114.8M | +40% |
| Q4 2024 | $117.5M | +59% |
ADMA's revenue is growing: $141M last quarter, up 5.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 48% | +10 points |
| Q2 2026 | 42% | +7.1 points |
| Q1 2026 | 51% | +21 points |
| Q4 2025 | 45% | +13 points |
| Q3 2025 | 38% | +4.9 points |
| Q2 2025 | 35% | -1.5 points |
| Q1 2025 | 30% | +3.7 points |
| Q4 2024 | 33% | +13 points |
ADMA has the edge over LLY on profitability, with a higher operating margin.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ADMA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
ADMA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $15.4M | +$16.4M |
| Q2 2026 | $27.3M | +46% |
| Q1 2026 | $55.7M | +$80.1M |
| Q4 2025 | $34.6M | -27% |
| Q3 2025 | -$1.1M | -104% |
| Q2 2025 | $18.7M | -57% |
| Q1 2025 | -$24.4M | -$19.8M |
| Q4 2024 | $47.5M | +189% |
ADMA has burned cash in most quarters: $133M over the past year, about three times what it generated the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ADMA on cash flow, with more consistent year-over-year improvement.
ADMA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2% | -4.5M shares |
| 1 year | -7.7% | -18.8M shares |
| 3 years | -3.4% | -7.9M shares |
| 5 years | +77% | +98.4M shares |
| Available history | +206% | +152M shares |
ADMA has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $25.1M |
| Q2 2026 | $25.1M |
| Q1 2026 | $130.2M |
| Q4 2025 | $8.9M |
ADMA spent $189M buying back its own shares over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ADMA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.3x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.3x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | 0.1x | Very low |
| Q2 2025 | -0.6x | Net Cash |
| Q1 2025 | -0.5x | Net Cash |
| Q4 2024 | -0.7x | Net Cash |
ADMA has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ADMA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 69.1 | Neutral |
| Stochastic | 85.4 | Overbought |
ADMA's weekly RSI is 69 (neutral) and its Stochastic is 85 (overbought).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ADMA PE vs Healthcare Sector
| Metric | ADMA | Sector median | Relative |
|---|---|---|---|
| PE | 17x | 26x | 34% below |
| PE % | 28 | 29 | 1 pt below |
ADMA has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ADMA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.0 | 20% above |
| 20 week MA | $9.91 | 34% above |
| 50 week MA | $12.0 | 10% above |
| 100 week MA | $14.9 | 11% below |
| 200 week MA | $11.4 | 17% above |
ADMA's trend is mixed: it's above four of its five weekly moving averages, and 17% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ADMA on trend strength, trading above more of its moving averages.
ADMA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3.95 | $2.15 | -46% |
| 2021 | $2.15 | $1.27 | -41% |
| 2022 | $1.27 | $3.65 | +187% |
| 2023 | $3.65 | $4.52 | +24% |
| 2024 | $4.52 | $17.5 | +286% |
| 2025 | $17.5 | $19.3 | +10% |
| 2026 YTD | $19.3 | $13.2 | -31% |
ADMA's yearly returns have swung widely, from +286% in 2024 to −46% in 2020. It's down 31% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ADMA on returns for 2026, with the stronger performance.